Lite Strategy, Inc. (LITS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $25.30M
Last updated: Nov 17, 2026 at 11:05 AM ET
Lite Strategy, Inc. (LITS) Competitors
The companies most similar to Lite Strategy are Plus Therapeutics (PSTV), Estrella Immunopharma (ESLA) and Instil Bio (TIL). By market cap, Lite Strategy ranks 10th of the 13 companies on this page; Elicio Therapeutics (ELTX) is the largest at $42.46M.
Peer Comparison
LITS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Lite Strategy (LITS) | $25.30M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Plus Therapeutics Inc (PSTV) | $26.64M | N/A | 2.0x | -230.2% | -827.8% | -2.9% | 0.00% |
| Estrella Immunopharma Inc. (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| CEL-SCI Corp (CVM) | $22.51M | N/A | N/A | 0.0% | -109.0% | -62.7% | 0.00% |
| OS Therapies Incorporated (OSTX) | $34.87M | N/A | N/A | 0.0% | 218.0% | 0.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| INmune Bio Inc (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| Edesa Biotech Inc (EDSA) | $26.21M | N/A | N/A | 0.0% | N/A | -99.9% | 0.00% |
| Serina Therapeutics Inc (SER) | $36.93M | N/A | 288.7x | 0.0% | -109.4% | 154.9% | 0.00% |
| Transcode Therapeutics Inc (RNAZ) | $22.35M | N/A | N/A | 0.0% | -412.7% | 0.0% | 0.00% |
| Elicio Therapeutics Inc. (ELTX) | $42.46M | N/A | N/A | 0.0% | -96.6% | 0.0% | 0.00% |
| Peer median | $30.91M | N/A | 145.4x | 0.0% | -109.0% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to Lite Strategy, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Plus Therapeutics Inc (PSTV) | Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing... | PSTV competitors |
| Estrella Immunopharma Inc. (ESLA) | Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. | ESLA competitors |
| Instil Bio Inc. (TIL) | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| CEL-SCI Corp (CVM) | CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. | CVM competitors |
| OS Therapies Incorporated (OSTX) | OS Therapies Incorporated is a pioneering biopharmaceutical company committed to developing innovative treatments for unmet medical needs... | OSTX competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
| INmune Bio Inc (INMB) | INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer, Alzheimer's disease... | INMB competitors |
| Edesa Biotech Inc (EDSA) | Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, is engaged in the research and development... | EDSA competitors |
| Serina Therapeutics Inc (SER) | Serina Therapeutics Inc is a pioneering biotechnology company focused on developing innovative solutions for unmet medical needs in oncology and neurology... | SER competitors |
| Transcode Therapeutics Inc (RNAZ) | TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic... | RNAZ competitors |
| Elicio Therapeutics Inc. (ELTX) | Elicio Therapeutics Inc. (ELTX) is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer treatment. | ELTX competitors |
Frequently Asked Questions About LITS
Who are Lite Strategy's main competitors?
The companies most similar to Lite Strategy include Plus Therapeutics (PSTV), Estrella Immunopharma (ESLA), Instil Bio (TIL), CEL-SCI (CVM) and OS Therapies (OSTX), listed from the closest match.
Who is Lite Strategy's biggest competitor?
Elicio Therapeutics (ELTX) is the largest of the similar companies at $42.46M; Plus Therapeutics (PSTV) is the closest match by business profile, size, sector and industry.
How does LITS stock compare with its competitors?
LITS' net margin is 0.0% against a peer median of 0.0%.
Which of Lite Strategy's competitors pays a higher dividend?
Lite Strategy pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Lite Strategy bigger than its competitors?
No. Lite Strategy is 10th by market cap among the 13 companies on this page; the largest is Elicio Therapeutics (ELTX) at $42.46M.
LITS pages: Overview, Earnings, Financials, Competitors